• Male or female participants ≥18 years

• Willing and able to comply with clinic visits and study-related procedures

• Chronic AD present for at least 1 year prior to screening

• Have vIGA score of ≥3 (5-scale of 0 to 4) at baseline

• Have ≥10% BSA of AD involvement at baseline

• Have EASI ≥18 at screening and baseline

• History of inadequate response to, intolerance to or contraindication to a stable regimen of topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI) as treatment for AD

• All participants must have previously been treated with dupilumab meeting one of the following conditions:

‣ Participants who stopped dupilumab treatment due to non-response, partial response, loss of efficacy must have been previously treated with dupilumab for at least 16 weeks duration;

⁃ Participants who stopped dupilumab treatment due to intolerance or adverse events (AEs) to the drug may enter the study with no required prior length of dupilumab treatment;

⁃ Participants who stopped dupilumab treatment due to cost or loss of access to dupilumab or for any other reasons may enter the study with no required prior length of dupilumab treatment;